Semaglutide vs Tirzepatide: How to Choose

The difference is how many pathways each one acts on.

Your gut releases hormones called incretins after you eat. They signal fullness, slow how quickly the stomach empties, and help regulate blood sugar. Semaglutide imitates one of them — GLP-1. Tirzepatide imitates two — GLP-1 and GIP.

That is the whole structural difference, and the rest follows from it. Tirzepatide is a newer molecule acting on a broader set of receptors. Semaglutide has been in wider clinical use for longer, which means a longer real-world track record.

Is tirzepatide better than semaglutide?

Neither of those facts tells you which is right for you. People respond differently to each and tolerate each differently, and some medical histories make these medications inappropriate altogether. What the physician review settles is whether treatment is appropriate for you and at what dose — the choice between the two is yours, made when you start a plan.

Tirzepatide vs semaglutide side effects

Both are in the same drug class and share the same side effect profile. The common ones are digestive: nausea, constipation, diarrhoea, stomach discomfort, and reflux. They tend to appear early, tend to be related to dose, and tend to settle as your body adjusts — which is exactly why both start at the lowest dose and step up slowly rather than starting where you will finish.

Less common but more serious effects are possible with both, including inflammation of the pancreas and gallbladder problems. Before prescribing either medication, your physician reviews your personal and family medical history — including any history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, or gallbladder disease. Some histories make these medications inappropriate.

If you experience severe or persistent abdominal pain at any point, stop and contact a clinician.

Anyone who tells you one of these has no side effects is not describing a medication.

Who decides the dose?

By your physician, based on how you respond — not by a chart.

Both medications start at the lowest dose. Your physician reviews how you are tolerating it and whether it is working before adjusting. Some people stay at a lower dose for a long time because it is doing the job. Some move up. Some need to come back down.

This is the part of treatment that is genuinely individual, and it is the reason a prescription weight-loss programme is a relationship rather than a purchase. Changing your own dose — up or down — without telling your prescriber is how side effects become problems.

Switching from semaglutide to tirzepatide

Yes, and people do. It is a clinical decision made with your physician, not a change you make on your own.

The two are not interchangeable at equivalent doses. They act on different receptors, and the amount of one you have been taking does not translate directly into an amount of the other. Switching means your physician sets a new starting point and adjusts from there — which usually means starting lower than you might expect and stepping up again.

The usual reasons to consider switching are tolerance, response, or cost. All three are worth raising. If you are already a patient, message your care team. If you are coming from another provider, note your current medication and dose in your intake so the physician reviewing it has the full picture.

Which one costs less?

Semaglutide, at every plan length. Month to month it is $191 against $239. On the 12-month plan it is $99 a month against $149.

That is the full cost. There is no consultation fee, no membership fee, and no separate charge for the physician review. Insurance is not required and is not billed — the price is the price, whatever your coverage is or is not.

The longer plans cost less per month because they are paid up front. Worth being clear about the trade: a 12-month plan is a 12-month commitment, and it is the cheaper option only if you intend to be treated for a year. Month to month costs more and commits to nothing. Neither is the right answer for everyone.

Who chooses, you or the physician?

You choose — and it is worth saying that plainly, because a lot of pages in this category imply otherwise.

When you start a plan you select semaglutide or tirzepatide. That selection is what your intake is reviewed against. The physician review that follows decides whether treatment is appropriate for you at all and sets your starting dose. It does not quietly swap one medication for the other — if the physician concludes the medication you selected is not appropriate for you, you are told, rather than dispensed something you did not choose.

For most people the deciding factors are practical: cost, how long you want to commit for, and how you have responded to a GLP-1 before. Where your history matters most — a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, or gallbladder disease — it usually bears on whether either medication is appropriate, not on which one.

What happens after you choose

A licensed physician reviews every intake — a person, not an algorithm — and either prescribes, asks follow-up questions, or determines that treatment is not appropriate. That last outcome is real and it happens; in that case the order is cancelled and you are refunded in full.

If a medication is prescribed, it ships from a licensed 503A compounding pharmacy, and your care team stays available for dose adjustments and questions.